Search Within

Mary Ellen Moynahan

Formats
  1. Journal Article (56)
  2. Meeting Abstract (46)
  3. Conference Paper (2)
  4. Book Section (1)
Groups
  1. Breast Medicine Service (105)
  2. Department of Medicine (105)
  3. Solid Tumor Oncology Division (105)
  4. Survivorship Research (59)
  5. GSK Faculty (52)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (49)

More Groups

People
  1. Clifford Hudis (54)
  2. Larry Norton (38)
  3. Maria Jasin (30)
  4. Andrew Seidman (28)
  5. Teresa Gilewski (26)
  6. Gabriella D'Andrea-Carlino (25)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (2)
  4. 2017 (2)
  5. 2016 (9)
  6. 2015 (10)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Cancer Research (14)
  3. Breast Cancer Research and Treatment (12)
  4. Clinical Cancer Research (8)
  5. Proceedings of the National Academy of Sciences of the United States of America (4)
  6. Clinical Breast Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. American Association for Cancer Research (23)
  3. Springer (12)
  4. Elsevier Inc. (11)
  5. Nature Publishing Group (5)
  6. Cell Press (4)

More Publishers

Results (105)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)
    Meeting Abstract

    Dickler, M. N.; Barry, W. T.; Cirrincione, C. T.; Ellis, M. J.; Moynahan, M. E.; Innocenti, F.; Hurria, A.; Rugo, H. S.; Lake, D.; Hahn, O. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC)
    Meeting Abstract

    Lowery, M. A.; Kelsen, D. P.; Smith, S. C.; Moore, M.; Kindler, H. L.; Golan, T.; Segal, A.; Hollywood, E.; Maynard, H.; Capanu, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC)
    Meeting Abstract

    O'Reilly, E. M.; Lowery, M. A.; Segal, M. F.; Smith, S. C.; Moore, M. J.; Kindler, H. L.; Golan, T.; Segal, A.; Salo-Mullen, E. E.; Hollywood, E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Evaluation of PARP inhibition as a platinum sparing strategy in BRCA2-deficient pancreatic tumors
    Meeting Abstract

    Lowery, M. A.; Lee, A.; Tobias, E.; Sung, P.; Bhanot, U.; Shakya, R.; Ludwig, T.; O'Reilly, E. M.; Jasin, M.; Moynahan, M. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save